Stockholm - Delayed Quote SEK
Stayble Therapeutics AB (publ) (STABL.ST)
0.3985
-0.0015
(-0.38%)
At close: May 16 at 5:17:04 PM GMT+2
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andreas Gerward M.Sc. | Co-Founder & CEO | -- | -- | 1988 |
| Mr. Mattias Munnich M.Sc. | Co-Founder | -- | -- | 1979 |
| Mr. Erik Kullgren | Chief Financial Officer | -- | -- | -- |
| Mr. Anders Lehmann Ph.D. | Chief Scientific Officer | -- | -- | 1957 |
Stayble Therapeutics AB (publ)
Lennart Torstenssonsgatan 6
Gothenburg, 412 56
Sweden
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 2
Description
Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration. The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Corporate Governance
Stayble Therapeutics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
7XB.F Xbrane Biopharma AB
0.0214
+19.55%
EGTX.ST Egetis Therapeutics AB (publ)
3.2550
-4.26%
ISOFOL.ST Isofol Medical AB (publ)
1.4400
+0.56%
ONCO.ST Oncopeptides AB (publ)
2.0000
+2.56%
VICO.ST Vicore Pharma Holding AB (publ)
8.54
-0.12%
XBRANE.ST Xbrane Biopharma AB (publ)
0.2550
+4.34%
MRNA Moderna, Inc.
24.86
+5.12%